Erythropoietic protoporphyria: the light disease melanocortins learned to treat

A pathway that stops one step short of heme — and a body that answers the mistake with a pigment the melanocortin system already knew how to build.

Most pages on this site start from a receptor and work outward to what it does. This one starts from a disease and works back to why the melanocortin system turned out to be the answer. Erythropoietic protoporphyria is a rare inherited disorder of how the body builds heme — the iron-centred molecule that carries oxygen in blood and sits at the heart of countless enzymes. It is also the first condition for which the melanocortin pigment switch, MC1R, was deliberately turned into an approved drug.^[3]

A pathway that stops one step short

Heme is assembled in eight enzymatic steps. The very last one is carried out by an enzyme called ferrochelatase, whose single job is to insert an iron atom into the finished ring — a molecule called protoporphyrin IX(PPIX) — to complete heme. In EPP, ferrochelatase activity is reduced, typically to somewhere around a third of normal. The pathway runs right up to PPIX and then stalls, so PPIX accumulates in red blood cell precursors, spills into the plasma, and reaches the skin.^[1]

The genetics are quietly interesting. Most patients are not simple recessives: they carry a severe loss-of-function mutation in the ferrochelatase gene on one chromosome and, on the other, a common low-expression variant (the “IVS3-48C” allele) that much of the population also carries harmlessly. Only when a damaging mutation lands opposite that weak allele does total activity fall far enough for disease — which is why EPP can appear to move through a family in a way that looks neither cleanly dominant nor cleanly recessive.^[1] A small minority have a closely related disease, X-linked protoporphyria, where the problem is an overactive upstream enzyme making too much PPIX rather than a failure to clear it — same molecule, same light reaction, different starting point.^[1]

Why light becomes pain

PPIX is not an inert waste product. It is a photosensitiser: a molecule built to absorb light. Its strongest absorption sits in the violet-blue band around 400–410 nm — visible light, not ultraviolet. When sunlight reaches PPIX sitting in the small blood vessels of the skin, the molecule is kicked into an excited state and passes that energy to nearby oxygen, generatingreactive oxygen species that damage the vessel walls and surrounding tissue. The result is not a slow burn but an immediate, stinging, burning pain, often with swelling and redness, within minutes of exposure.^[1]

This is the detail that sets EPP apart from ordinary sun sensitivity, and the reason it is so often missed for years. Because the trigger is visible light rather than UV, it passes through ordinary window glass and through cloud; sunscreen aimed at UV does little; and the reaction is pain in real time rather than a sunburn that shows up hours later. Children with EPP learn to fear sunny windows and car rides, and the diagnosis is frequently delayed because the skin may show no blister to point to — only a child in agony with, to an onlooker, nothing visibly wrong.^[1]

The cost beyond the skin

EPP is dominated by the skin, but it is not only a skin disease. The excess PPIX is cleared by the liver into bile, and that load can form gallstones and, in a small but serious fraction of patients, overwhelm the liver and threaten protoporphyric liver failure. Many patients are also mildly anaemic. None of this changes the day-to-day reality — a life organised around avoiding light — but it is why EPP is monitored as a whole-body condition and not treated as a cosmetic nuisance.^[1]

Where the melanocortin system comes in

For most of its history EPP had no treatment at all, only avoidance: heavy clothing, shade, and a life lived around the sun. The insight that changed things did not come from fixing the enzyme. It came from the other end — from the skin’s own defence. The pigment α-MSH normally drives, eumelanin, happens to be an excellent absorber of exactly the visible light that excites PPIX. Build up more of it, and you put a shield between the light and the culprit molecule.

That is precisely what afamelanotide (Scenesse) does. It is a durable copy of α-MSH that switches on MC1R to lay down protective eumelaninindependent of sunlight — so a person who cannot safely tan the normal way can still accumulate the pigment that buys them time in the light. In the pivotal trials, patients given the implant spent significantly more pain-free time in sunlight than those given placebo.^[2] On the strength of that, the FDA approved it on8 October 2019, the first therapy ever cleared for EPP.^[3]

The approach is now being pushed from implant toward pill. Dersimelagon, an oral small-molecule MC1R agonist, drives the same pigment response by mouth; a Phase 2 trial reported in 2023 showed it lengthened the time EPP patients could tolerate sunlight before symptoms began.^[4] Both drugs share the same logic and the same honest limit: they treat the light reaction, not the enzyme. PPIX still accumulates; the liver risk is unchanged; what improves is how much daylight a person can bear.

The honest bottom line

EPP is a clean illustration of the theme this whole site runs on — one economical system, reused far from where you would expect. A defect in heme chemistry, with nothing obviously to do with pigment, turned out to be best managed by borrowing the melanocortin pigment switch and running it on purpose. It is not a cure, and the field is still working toward one that addresses the protoporphyrin itself. But it is a real answer to a disease that had none, and it is where MC1R pharmacology first proved it could leave the laboratory. For the drug, see afamelanotide; for the oral successor, see dersimelagon; for the receptor they both act on, see MC1R — the pigment switch.